{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T19:11:05Z","timestamp":1785352265493,"version":"3.55.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T00:00:00Z","timestamp":1722556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T00:00:00Z","timestamp":1722556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-024-09595-4","type":"journal-article","created":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T09:04:54Z","timestamp":1722589494000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Potential healthcare resource use and associated costs of every 2 month injectable cabotegravir plus rilpivirine long-acting regimen implementation in the Spanish National Healthcare System compared to daily oral HIV treatments"],"prefix":"10.1186","volume":"24","author":[{"given":"Laura-Amanda Vallejo","family":"Aparicio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria Neches","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Hern\u00e1ndez-Novoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregorio","family":"Casado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferr\u00e1n","family":"Jodar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Pinel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Callejo","family":"Velasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,2]]},"reference":[{"key":"9595_CR1","unstructured":"Global Report. UNAIDS report on the global AIDS epidemic 2021. https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/UNAIDS_FactSheet_en.pdf."},{"key":"9595_CR2","unstructured":"United Nations. World Leaders in General Assembly Adopt Political Declaration Pledging Urgent, Transformative Action to Stop Global AIDS Epidemic by 2030 [press release]. https:\/\/press.un.org\/en\/2021\/ga12333.doc.htm."},{"issue":"21","key":"9595_CR3","first-page":"250","volume":"30","author":"Centers for Disease Control (CDC)","year":"1981","unstructured":"Centers for Disease Control (CDC). Pneumocystis pneumonia\u2013Los Angeles. MMWR Morb Mortal Wkly Rep. 1981;30(21):250\u20132.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"9595_CR4","unstructured":"Ministerio de Sanidad. Vigilancia epidemiol\u00f3gica del VIH y SIDA en Espa\u00f1a 2020. Actualizaci\u00f3n 30 de junio de 2021. November 2021. https:\/\/www.sanidad.gob.es\/ciudadanos\/enfLesiones\/enfTransmisibles\/sida\/vigilancia\/Informe_VIH_SIDA_WEB.pdf."},{"key":"9595_CR5","unstructured":"Unidad de vigilancia del VIH, ITS y hepatitis. Actualizaci\u00f3n del Continuo de Atenci\u00f3n del VIH en Espa\u00f1a, 2017\u20132019. Madrid: Centro Nacional de Epidemiolog\u00eda \u2013 Instituto de Salud Carlos III \/ Plan Nacional sobre el Sida \u2013 Direcci\u00f3n General de Salud P\u00fablica. 2020. Disponible en: https:\/\/www.sanidad.gob.es\/ciudadanos\/enfLesiones\/enfTransmisibles\/sida\/vigilancia\/ESTIMACION_DEL_CONTINUO_DE_ATENCIoN_DEL_VIH_EN_ESPAnA_Nov2020.pdf [Acceso: febrero 2023]."},{"key":"9595_CR6","unstructured":"DIRECCI\u00d3N GENERAL DE SALUD P\u00daBLICA. VIGILANCIA EPIDEMIOL\u00d3GICA DEL, VIH y SIDA, EN ESPA\u00d1A. 2021 https:\/\/www.isciii.es\/QueHacemos\/Servicios\/VigilanciaSaludPublicaRENAVE\/EnfermedadesTransmisibles\/Documents\/VIH\/informes%20de%20vigilancia%20VIH%20y%20sida%20anteriores\/Informe%20VIH_SIDA_2022_CCAA.pdf."},{"issue":"3","key":"9595_CR7","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1097\/qad.0000000000001335","volume":"31","author":"A Gueler","year":"2017","unstructured":"Gueler A, Moser A, Calmy A, G\u00fcnthard HF, Bernasconi E, Furrer H, et al. Life expectancy in HIV-positive persons in Switzerland: matched comparison with general population. Aids. 2017;31(3):427\u201336. https:\/\/doi.org\/10.1097\/qad.0000000000001335. Epub 2016\/11\/11.","journal-title":"Aids"},{"issue":"5","key":"9595_CR8","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1097\/coh.0000000000000298","volume":"11","author":"G Wandeler","year":"2016","unstructured":"Wandeler G, Johnson LF, Egger M. Trends in life expectancy of HIV-positive adults on antiretroviral therapy across the globe: comparisons with general population. Curr Opin HIV AIDS. 2016;11(5):492\u2013500. https:\/\/doi.org\/10.1097\/coh.0000000000000298. Epub 2016\/06\/03.","journal-title":"Curr Opin HIV AIDS"},{"issue":"12","key":"9595_CR9","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1093\/cid\/ciu701","volume":"59","author":"J Schouten","year":"2014","unstructured":"Schouten J, Wit FW, Stolte IG, Kootstra NA, van der Valk M, Geerlings SE, et al. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin Infect Dis. 2014;59(12):1787\u201397. https:\/\/doi.org\/10.1093\/cid\/ciu701. Epub 2014\/09\/04.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"9595_CR10","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1097\/coh.0000000000000305","volume":"11","author":"KN Althoff","year":"2016","unstructured":"Althoff KN, Smit M, Reiss P, Justice AC. HIV and ageing: improving quantity and quality of life. Curr Opin HIV AIDS. 2016;11(5):527\u201336. https:\/\/doi.org\/10.1097\/coh.0000000000000305. Epub 2016\/07\/02.","journal-title":"Curr Opin HIV AIDS"},{"issue":"4","key":"9595_CR11","doi-asserted-by":"publisher","first-page":"127","DOI":"10.7399\/fh.11367","volume":"44","author":"M Gimeno-Gracia","year":"2020","unstructured":"Gimeno-Gracia M, S\u00e1nchez-Rubio-Ferr\u00e1ndez J, Robustillo-Cort\u00e9s MLA, Morillo-Verdugo R. Prevalence of polypharmacy and pharmacotherapy complexity in elderly people living with HIV in Spain. POINT study. Farm Hosp. 2020;44(4):127\u201334. https:\/\/doi.org\/10.7399\/fh.11367. Epub 2020\/07\/11.","journal-title":"Farm Hosp"},{"key":"9595_CR12","doi-asserted-by":"publisher","first-page":"e349","DOI":"10.1016\/S2352-3018(17)30066-8","volume":"4","author":"Collaboration Antiretroviral Therapy Cohort","year":"2017","unstructured":"Collaboration Antiretroviral Therapy Cohort. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV. 2017;4:e349\u201356.","journal-title":"Lancet HIV"},{"key":"9595_CR13","unstructured":"Joint United Nations Programme on HIV\/AIDS (UNAIDS). Fast-Track: ending the AIDS epidemic by 2030. 2014."},{"key":"9595_CR14","unstructured":"Joint United Nations Programme on HIV\/AIDS (UNAIDS). 2025 AIDS TARGETS. Available at: https:\/\/aidstargets2025.unaids.org\/# [Accessed: march 2023]. 2014."},{"issue":"1","key":"9595_CR15","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12916-016-0640-4","volume":"14","author":"JV Lazarus","year":"2016","unstructured":"Lazarus JV, Safreed-Harmon K, Barton SE, Costagliola D, Dedes N, del Amo Valero J, et al. Beyond viral suppression of HIV \u2013 the new quality of life frontier. BMC Med. 2016;14(1):94. https:\/\/doi.org\/10.1186\/s12916-016-0640-4.","journal-title":"BMC Med"},{"key":"9595_CR16","doi-asserted-by":"publisher","unstructured":"Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV. NATURE COMMUNICATIONS. (2021) 12:4450. https:\/\/doi.org\/10.1038\/s41467-021-24673-w.","DOI":"10.1038\/s41467-021-24673-w"},{"key":"9595_CR17","unstructured":"Panel de expertos de GeSIDA y Divisi\u00f3n de control de VIH, ITS, Hepatitis virales y Tuberculosis. Plan Nacional sobre el Sida. (2022) Documento de consenso de GeSIDA\/Plan Nacional sobre el SIDA respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana. https:\/\/gesida-seimc.org\/wp-content\/uploads\/2022\/05\/GuiaGeSIDAPlanNacionalSobreElSidaRespectoAlTratamientoAntirretroviralEnAdultosInfectadosPorElVirusDeLaInmunodeficienciaHumanaActualizacionEnero2022.pdf."},{"key":"9595_CR18","unstructured":"European AIDS Clinical Society (EACS). (2021) EACS Guidelines version 11.0, October 2021. https:\/\/www.eacsociety.org\/media\/final2021eacsguidelinesv11.0_oct2021.pdf."},{"issue":"1","key":"9595_CR19","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1001\/jama.2022.22246","volume":"329","author":"RT Gandhi","year":"2023","unstructured":"Gandhi RT, Bedimo R, Hoy JF, Landovitz RJ, Smith DM, Eaton EF, et al. Antiretroviral Drugs for Treatment and Prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society\u2013USA panel. JAMA. 2023;329(1):63\u201384. https:\/\/doi.org\/10.1001\/jama.2022.22246.","journal-title":"JAMA"},{"issue":"1","key":"9595_CR20","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/COH.0000000000000708","volume":"17","author":"SH Bares","year":"2022","unstructured":"Bares SH, et al. Curr Opin HIV AIDS. 2022;17(1):22\u201331.","journal-title":"Curr Opin HIV AIDS"},{"issue":"6","key":"9595_CR21","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s40265-020-01284-1","volume":"80","author":"AI Rana","year":"2020","unstructured":"Rana AI, et al. Drugs. 2020;80(6):535\u201345.","journal-title":"Drugs"},{"key":"9595_CR22","unstructured":"European Medicines Agency. VOCABRIA https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vocabria."},{"issue":"1","key":"9595_CR23","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/coh.0000000000000606","volume":"15","author":"R D\u2019Amico","year":"2020","unstructured":"D\u2019Amico R, Margolis DA. Long-acting injectable therapy: an emerging paradigm for the treatment of HIV infection. Curr Opin HIV AIDS. 2020;15(1):13\u20138. https:\/\/doi.org\/10.1097\/coh.0000000000000606. Epub 2019\/11\/26.","journal-title":"Curr Opin HIV AIDS"},{"key":"9595_CR24","unstructured":"DHHS Guidelines for the use of antiretroviral agents in adults and adolescents with HIV, Sept. 2022. https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/adult-adolescent-arv\/guidelines-adult-adolescent-arv.pdf (accessed December 2022)."},{"key":"9595_CR25","unstructured":"GESIDA Guidelines National Plan on AIDS regarding the antiretroviral treatment in adults infected with HIV. Jan 2022. https:\/\/gesida-seimc.org\/wp-content\/uploads\/2022\/03\/plan_nacional_gesida_tratamiento_antirretroviral.pdf (accessed December 2022)."},{"issue":"2","key":"9595_CR26","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1093\/jac\/dkab324","volume":"77","author":"P Thoueille","year":"2022","unstructured":"Thoueille P, Choong E, Cavassini M, Buclin T, Decosterd LA. Long-acting antiretrovirals: a new era for the management and prevention of HIV infection. J Antimicrob Chemother. 2022;77(2):290\u2013302. https:\/\/doi.org\/10.1093\/jac\/dkab324. Epub 2021\/09\/10.","journal-title":"J Antimicrob Chemother"},{"key":"9595_CR27","unstructured":"ClinicalTrials.gov. Study to evaluate the efficacy, Safety, and tolerability of long-acting intramuscular cabotegravir and Rilpivirine for Maintenance of Virologic suppression following switch from an Integrase Inhibitor in HIV-1 infected Therapy Naive Participants (FLAIR) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02938520."},{"key":"9595_CR28","unstructured":"ClinicalTrials.gov. Study evaluating the efficacy, Safety, and tolerability of switching to long-acting Cabotegravir Plus Long-acting Rilpivirine from current antiretroviral regimen in Virologically suppressed HIV-1-infected adults (ATLAS) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02951052?term=NCT02951052&draw=2&rank=1."},{"key":"9595_CR29","unstructured":"ClinicalTrials.gov. Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA\u2009+\u2009RPV LA) in human-immunodeficiency Virus-1 (HIV-1) infected adults (ATLAS-2M) https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03299049."},{"issue":"10267","key":"9595_CR30","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1016\/s0140-6736(20)32666-0","volume":"396","author":"ET Overton","year":"2021","unstructured":"Overton ET, Richmond G, Rizzardini G, Jaeger H, Orrell C, Nagimova F, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2\u00a0M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet. 2021;396(10267):1994\u20132005. https:\/\/doi.org\/10.1016\/s0140-6736(20)32666-0. Epub 2020\/12\/15.","journal-title":"Lancet"},{"key":"9595_CR31","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.1007\/s10461-020-02929-8","volume":"24","author":"M Murray","year":"2020","unstructured":"Murray M, Antela A, Mills A, et al. Patient-reported outcomes in ATLAS and FLAIR participants on long-acting regimens of cabotegravir and ilpivirina over 48 weeks. AIDS Behav. 2020;24:3533\u201344.","journal-title":"AIDS Behav"},{"key":"9595_CR32","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1007\/s40121-023-00840-y","volume":"12","author":"S Moreno","year":"2023","unstructured":"Moreno S, Rivero A, Ventayol P, et al. Cabotegravir and Rilpivirine Long-acting antiretroviral therapy administered every 2 months is cost-effective for the treatment of HIV-1 in Spain. Infect Dis Ther. 2023;12:2039\u201355. https:\/\/doi.org\/10.1007\/s40121-023-00840-y.","journal-title":"Infect Dis Ther"},{"issue":"10","key":"9595_CR33","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.18553\/jmcp.2020.26.10.1246","volume":"26","author":"R Bhattacharya","year":"2020","unstructured":"Bhattacharya R, Herren K, Poonawalla I, Bunniran S, Bloomfield A, Schwab P. Comparing medical utilization and cost outcomes in oral Versus Injectable Immunotherapy users with chronic inflammatory joint and skin diseases. J Manag Care Spec Pharm. 2020;26(10):1246\u201356. https:\/\/doi.org\/10.18553\/jmcp.2020.26.10.1246. Epub 2020\/10\/01.","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"9595_CR34","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1080\/14017430601049449","volume":"12","author":"J Vidal-Alaball","year":"2006","unstructured":"Vidal-Alaball J, Butler CC, Potter CC. Comparing costs of intramuscular and oral vitamin B12 administration in primary care: a cost-minimization analysis. Eur J Gen Pract. 2006;12(4):169\u201373. Epub 2006\/11\/28. doi: 10.1080\/14017430601049449. PubMed PMID: 17127603.","journal-title":"Eur J Gen Pract"},{"issue":"2","key":"9595_CR35","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3111\/13696998.2012.751025","volume":"16","author":"S Offord","year":"2013","unstructured":"Offord S, Wong B, Mirski D, Baker RA, Lin J. Healthcare resource usage of schizophrenia patients initiating long-acting injectable antipsychotics vs oral. J Med Econ. 2013;16(2):231\u20139. https:\/\/doi.org\/10.3111\/13696998.2012.751025.","journal-title":"J Med Econ"},{"key":"9595_CR36","first-page":"22denoviembrede","volume":"n\u2013m 226","author":"Servicio de Salud","year":"2017","unstructured":"Servicio de Salud. Resoluci\u00f3n De 15 de noviembre de 2017. Diario Oficial De Castilla-La Mancha. 2017;n\u2013m 226:22denoviembrede2017.","journal-title":"Diario Oficial De Castilla-La Mancha"},{"key":"9595_CR37","first-page":"5deenerode2022","volume":"n\u2013mero 3","author":"Osakidetza-Servicio Vasco de Salud","year":"2021","unstructured":"Osakidetza-Servicio Vasco de Salud. Acuerdo De 13 de diciembre de 2021. Bolet\u00edn Oficial Del Pa\u00eds Vasco. 2021;n\u2013mero 3:5deenerode2022.","journal-title":"Bolet\u00edn Oficial Del Pa\u00eds Vasco"},{"key":"9595_CR38","unstructured":"Instituto Nacional de Estad\u00edstica (INE). Indice de precios de consumo (IPC). Medias anuales. Consultado: junio 2022."},{"key":"9595_CR39","unstructured":"Ramgopal et al. CROI 2023; Virtual and Seattle, WA. Oral presentation 191."},{"key":"9595_CR40","unstructured":"Gutner C et al. Cabotegravir And Rilpivirine Implementation Study in European Locations (CARISEL): examining healthcare staff attitudes during a hybrid III implementation-effectiveness trial implmenting cabotegravir\u2009+\u2009rilpivirine long-acting injectable (CAB\u2009+\u2009RPV LA) for people living with HIV. Poster presented at: 18th European AIDS Conference; October 27\u201330, 2021, virtual and London, United Kingdom. Poster PE2\/56."},{"key":"9595_CR41","unstructured":"Gutner C et al. Healthcare staff perspectives on the implementation of HIV injectable treatment: interim results from the Cabotegravir And Rilpivirine Implementation Study in European Locations (CARISEL). Poster presented at: 18th European AIDS Conference; October 27\u201330, 2021, virtual and London, United Kingdom. Poster PE2\/36."},{"key":"9595_CR42","unstructured":"Hocqueloux L et al. Perspectives on the acceptability, appropiateness, feasibility, barriers, and facilitators from patients receiving cabotegravir\u2009+\u2009rilpivirine long-acting injectable treatment (CAB\u2009+\u2009RPV LA): interim results from the Cabotegravir And Rilpivirine Implementation Study in European Locations (CARISEL). Poster presented at: 18th European AIDS Conference; October 27\u201330, 2021, virtual and London, United Kingdom."},{"issue":"4","key":"9595_CR43","first-page":"208","volume":"46","author":"MA Calleja-Hern\u00e1ndez","year":"2022","unstructured":"Calleja-Hern\u00e1ndez MA, Mart\u00ednez-Sesmero JM, Vallejo-Aparicio LA, Hern\u00e1ndez-Novoa B, Badia X. En representaci\u00f3n del Grupo de estudio CAB\u2009+\u2009RPV AP MCDA. Contribuci\u00f3n De cabotegravir\u2009+\u2009rilpivirina de acci\u00f3n prolongada al tratamiento de la infecci\u00f3n por VIH-1. Farm Hosp. 2022;46(4):208\u201314.","journal-title":"Farm Hosp"},{"key":"9595_CR44","unstructured":"Ministerio de Sanidad. Centros, servicios y establecimientos sanitarios. Centros y Servicios del Sistema Nacional de Salud. Accessed: 01\/09\/2022."},{"key":"9595_CR45","first-page":"522","volume-title":"Methods for the economic evaluation of health care programmes","author":"MF Drummond","year":"2015","unstructured":"Drummond MF, Sculpher MJ, Claxton K, et al. Methods for the economic evaluation of health care programmes. 4th ed. Oxford: Oxford University Press; 2015. p. 522.","edition":"4"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-09595-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-024-09595-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-09595-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T09:05:26Z","timestamp":1722589526000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-024-09595-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,2]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["9595"],"URL":"https:\/\/doi.org\/10.1186\/s12879-024-09595-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3872460\/v1","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,2]]},"assertion":[{"value":"17 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Laura-Amanda Vallejo Aparicio is employee and holds stocks of GSK group of companies; Victoria Neches Garc\u00eda is employee of GSK group of companies; Beatriz Hern\u00e1ndez-Novoa is employee and holds stocks of ViiV Healthcare; Gregorio Casado, Ferr\u00e1n Jodar, Marco Pinel and Daniel Callejo Velasco are employees of IQVIA. IQVIA received fees from ViiV Healthcare for conducting the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All interviews were conducted considering the current regulation on the protection of personal data and pharmacovigilance and in accordance to the EPHMRA Code of Conduct 2022. Given that this study met all requirements to be considered a market research study, according to the EPHMRA Code of Conduct 2022 it did not require Clinical Research Ethics Committee or Independent Review Board approval. HCPs involved received economic compensation for their participation in the project.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"775"}}